1. Home
  2. NMRA vs IAS Comparison

NMRA vs IAS Comparison

Compare NMRA & IAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • IAS
  • Stock Information
  • Founded
  • NMRA 2019
  • IAS 2009
  • Country
  • NMRA United States
  • IAS United States
  • Employees
  • NMRA N/A
  • IAS N/A
  • Industry
  • NMRA
  • IAS Computer Software: Programming Data Processing
  • Sector
  • NMRA
  • IAS Technology
  • Exchange
  • NMRA Nasdaq
  • IAS Nasdaq
  • Market Cap
  • NMRA 1.7B
  • IAS 1.8B
  • IPO Year
  • NMRA 2023
  • IAS 2021
  • Fundamental
  • Price
  • NMRA $2.05
  • IAS $10.04
  • Analyst Decision
  • NMRA Strong Buy
  • IAS Buy
  • Analyst Count
  • NMRA 6
  • IAS 11
  • Target Price
  • NMRA $20.67
  • IAS $14.80
  • AVG Volume (30 Days)
  • NMRA 6.3M
  • IAS 768.9K
  • Earning Date
  • NMRA 03-06-2025
  • IAS 02-25-2025
  • Dividend Yield
  • NMRA N/A
  • IAS N/A
  • EPS Growth
  • NMRA N/A
  • IAS 258.32
  • EPS
  • NMRA N/A
  • IAS 0.20
  • Revenue
  • NMRA N/A
  • IAS $511,358,000.00
  • Revenue This Year
  • NMRA N/A
  • IAS $11.97
  • Revenue Next Year
  • NMRA N/A
  • IAS $11.96
  • P/E Ratio
  • NMRA N/A
  • IAS $51.30
  • Revenue Growth
  • NMRA N/A
  • IAS 11.77
  • 52 Week Low
  • NMRA $1.83
  • IAS $7.98
  • 52 Week High
  • NMRA $21.00
  • IAS $17.53
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 20.26
  • IAS 43.77
  • Support Level
  • NMRA $2.12
  • IAS $9.86
  • Resistance Level
  • NMRA $2.44
  • IAS $10.15
  • Average True Range (ATR)
  • NMRA 0.39
  • IAS 0.31
  • MACD
  • NMRA -0.31
  • IAS -0.00
  • Stochastic Oscillator
  • NMRA 2.26
  • IAS 34.82

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About IAS Integral Ad Science Holding Corp.

Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.

Share on Social Networks: